Guideline for Diagnosis and Management of Immunotherapy‑Induced Colitis
Immediate Diagnostic Workup
Endoscopic Evaluation
Grade‑Based Treatment Algorithm
Grade 1 (Mild: < 4 additional stools/day)
Grade 2 (Moderate: 4–6 additional stools/day or abdominal pain/blood)
Grade 3–4 (Severe: ≥ 7 additional stools/day or hospitalization)
Second‑Line Biologic Therapy
Monitoring Treatment Response and Resuming Immunotherapy
Special Considerations
Management of Immune Checkpoint Inhibitor‑Induced Colitis – Guideline Summary
Diagnostic Workup
- Exclude infectious etiologies before any immunosuppression – obtain stool studies for Clostridioides difficile, bacterial pathogens, cytomegalovirus, and parasites. (ASCO, 2021) 6
- Measure fecal lactoferrin and calprotectin in all patients with grade ≥ 2 symptoms (≥ 4 extra stools/day) to stratify severity and prioritize endoscopic evaluation. (ASCO & AGA, 2021) [7][6]
- Perform colonoscopy with biopsies when feasible prior to high‑dose steroids; endoscopic ulceration predicts steroid‑refractory disease and supports early use of infliximab. (ASCO & AGA, 2021) [7][6]
- Reserve abdominal‑pelvic CT for patients with dominant severe abdominal pain, fever, or gastrointestinal bleeding to rule out perforation, abscess, or typhlitis; it is not required for isolated diarrhea. (ASCO & AGA, 2021) [7][6]
- Recognize rapid progression risk, especially with ipilimumab (anti‑CTLA‑4); prompt diagnostic workup and treatment initiation are critical. (AGA, 2021) 6
Grade‑Based Treatment Algorithm
Grade 1 (Mild – < 4 additional stools/day)
- Continue checkpoint inhibitor therapy (or hold briefly) and provide supportive care only – loperamide after infection exclusion, dietary adjustments, and dehydration monitoring. (ASCO, 2021) 7
- Monitor patients closely (e.g., telephone or electronic check‑ins every 3 days) until symptoms stabilize. (ASCO, 2021) 7
- Obtain gastroenterology consultation for prolonged grade 1 disease when endoscopic assessment may be warranted. (ASCO, 2021) 7
Grade 2 (Moderate – 4–6 additional stools/day)
- Immediately hold the checkpoint inhibitor. (ASCO, 2021) 7
- Start systemic corticosteroids at 1 mg/kg/day prednisone‑equivalent (unless diarrhea is clearly transient). (ASCO, 2021) 7
- Consult gastroenterology for all grade ≥ 2 cases and perform colonoscopy to identify ulceration, which guides early biologic therapy. (ASCO, 2021) 7
- If no improvement to grade ≤ 1 within 72 hours (steroid‑refractory), add infliximab 5 mg/kg or vedolizumab. (ASCO & AGA, 2021) [7][6]
- When symptoms improve to grade ≤ 1, taper corticosteroids over 4–6 weeks (shorter taper acceptable if biologic therapy is also used). (ASCO, 2021) 7
Grade 3–4 (Severe – ≥ 7 additional stools/day or hospitalization)
- Admit for inpatient management. (ASCO, 2021) 7
- Administer high‑dose corticosteroids 1–2 mg/kg/day prednisone‑equivalent. (ASCO, 2021) 7
- Obtain urgent colonoscopy and imaging to assess disease severity and exclude complications (perforation, abscess, typhlitis). (ASCO & AGA, 2021) [7][6]
- Add infliximab or vedolizumab early if steroid‑refractory within 72 hours or if high‑risk endoscopic features are present. (ASCO & AGA, 2021) [7][6]
- Consider permanent discontinuation of CTLA‑4 agents; PD‑1/PD‑L1 agents may be re‑initiated after recovery to grade ≤ 1. (ASCO, 2021) 7
Second‑Line Biologic Therapy
- Infliximab (5 mg/kg) and vedolizumab are the established second‑line agents with proven efficacy for steroid‑refractory or steroid‑dependent ICI‑colitis. (ASCO & AGA, 2021) [7][6]
Monitoring Treatment Response & Resuming Immunotherapy
- Aim for mucosal healing on repeat endoscopy and fecal calprotectin ≤ 116 mg/g before discontinuing biologic therapy. (ASCO, 2021) 7
- Repeat colonoscopy for grade ≥ 2 patients to document complete remission prior to restarting checkpoint inhibitors. (ASCO, 2021) 7
- Resuming PD‑1/PD‑L1 inhibitors carries a lower flare‑up risk than CTLA‑4 inhibitors. (ASCO, 2021) 7
- Checkpoint inhibitors may be resumed when: (a) corticosteroid taper is complete, (b) symptoms are ≤ grade 1, and (c) endoscopic/histologic remission is confirmed. (ASCO & AGA, 2021) [7][6]
- Screen for hepatitis B (surface antigen, core antibody, surface antibody) before initiating any biologic; repeat annually if biologic therapy extends beyond one year. (ASCO, 2021) 7
Additional Considerations
- Review and discontinue medications that alter the gut microbiome (e.g., proton‑pump inhibitors, antibiotics, probiotics) when managing ICI‑colitis. (ASCO, 2021) 7
- Budesonide is ineffective for prophylaxis but may be useful for treating ICI‑associated microscopic colitis. (AGA, 2021) 6
- Patients with pre‑existing inflammatory bowel disease have an increased risk of gastrointestinal adverse events but can still derive benefit from checkpoint blockade therapy. (AGA, 2021) 6
Management of Checkpoint Inhibitor-Induced Colitis
Established Treatment Algorithm
- Conservative management only with supportive care is recommended for grade 1 (mild) colitis, avoiding immunosuppressants due to lack of efficacy evidence 8
- High-dose systemic corticosteroids (0.5-2 mg/kg prednisone equivalent daily) are the first-line treatment for grade 2 or higher (moderate to severe) colitis, with tapering over 4-6 weeks once symptoms improve 9, 10, 11
- For steroid-refractory cases, infliximab (5 mg/kg) or vedolizumab are the established second-line agents 9, 10, 11
Diagnostic Steps
- Rule out infectious causes first with stool studies for C. difficile, bacterial pathogens, CMV, and parasites before initiating treatment 9, 10, 11
- Measure fecal lactoferrin and calprotectin to stratify risk and determine need for urgent endoscopy 9, 10, 11
- Endoscopic confirmation with colonoscopy and biopsy should be performed before initiating high-dose steroids when feasible 9, 10, 11
Treatment Considerations
- The American Gastroenterological Association recommends avoiding NSAIDs, as they are associated with increased incidence of ICI-induced colitis 8
- The American College of Gastroenterology suggests that azathioprine or mycophenolate may be used for steroid-refractory cases, though evidence is limited 8